Aytu Biopharma (AYTU) investor relations material

Executive summary

• EXXUA, a novel treatment for major depressive disorder (MDD), completed its first partial commercial launch quarter, generating $2.4 million in net revenue with over 1,300 prescriptions written by more than 450 unique prescribers and strong early adoption.

• The launch strategy emphasized targeted prescribers, disciplined investment, and leveraging the RxConnect platform to reduce access barriers and support adoption.

• Legacy ADHD and pediatric portfolios saw expected revenue declines due to strategic focus shift and generic competition, but remain profitable and provide cash flow to support EXXUA's growth.

• Suspended clinical development programs and divested unprofitable operations, including Consumer Health business, to focus on CNS medicines.

• Entered international agreements to commercialize ADHD products in Israel, the Palestinian Authority, and Canada.

Financial highlights

• Q3 net revenue was $12.4 million, down 33% year-over-year from $18.5 million, reflecting the transition from legacy products to EXXUA.

• Gross profit was $7.6 million (61% margin), down from $12.8 million (69%) year-over-year, impacted by a $700,000 inventory write-down.

• Net loss was $5.6 million ($0.53 per share), compared to net income of $4 million ($0.65 per share) in the prior year, impacted by launch investments and a $1.3 million derivative warrant liability loss.

• Adjusted EBITDA was -$2.8 million, down from +$3.9 million in the prior year.

• Cash and cash equivalents were $26.7 million at quarter end; stockholders' equity increased to $35.1 million after warrant reclassification.

Outlook and guidance

• Management expects mid to high 60% gross margins over time and a near-term path to profitability as EXXUA revenue builds.

• Planned increase in sales and marketing spend by $1–2 million in Q4 to support online campaigns and speaker programs; ongoing quarterly sales and marketing spend anticipated at $6–7 million.

• Focus remains on accelerating commercial business growth, achieving positive operating cash flows, and evaluating strategic transactions and partnerships.